4D Molecular Therapeutics (FDMT) Net Cash Flow: 2020-2025
Historic Net Cash Flow for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$28.6 million.
- 4D Molecular Therapeutics' Net Cash Flow fell 1779.37% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.8 million, marking a year-over-year decrease of 58.67%. This contributed to the annual value of -$99.8 million for FY2024, which is 150.71% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Net Cash Flow is -$28.6 million, which was up 50.02% from -$57.2 million recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Net Cash Flow peaked at $157.7 million during Q2 2023, and registered a low of -$152.8 million during Q3 2021.
- For the 3-year period, 4D Molecular Therapeutics' Net Cash Flow averaged around -$423,455, with its median value being -$15.8 million (2025).
- Its Net Cash Flow has fluctuated over the past 5 years, first soared by 859.10% in 2023, then tumbled by 1,779.37% in 2025.
- 4D Molecular Therapeutics' Net Cash Flow (Quarterly) stood at $62.0 million in 2021, then plummeted by 190.22% to -$55.9 million in 2022, then surged by 52.51% to -$26.6 million in 2023, then tumbled by 43.78% to -$38.2 million in 2024, then plummeted by 1,779.37% to -$28.6 million in 2025.
- Its last three reported values are -$28.6 million in Q3 2025, -$57.2 million for Q2 2025, and -$15.8 million during Q1 2025.